One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Geron Corporation
GERN · NMS · Healthcare · Biotechnology
Current price
$0.97
52-week range
$0.84 - $2.01
Market cap
$622.24M
Balance sheet
Healthy
-1.58x Concerning
Net cash $178.70M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
1 Risk
1 rewards · 1 risks
- Reward Revenue grew 86642.6% last year.
- Risk Return on equity was -28.3% last year — the company lost money on shareholders' equity.
What this company does
Geron Corporation
Geron Corporation is developing new medicines, mainly for blood cancers like myelodysplastic syndromes and myelofibrosis, with their key drug RYTELO already on the market. The money they make comes from selling these treatments, which is important because it funds their research into even more advanced therapies.
How the company got here
Geron Corporation started in 1990 as a company focused on a wide range of biotechnology research. Over the years, it has strategically narrowed its focus to concentrate on developing treatments for specific types of cancer. This shift involved significant research and development, including clinical trials to test the safety and effectiveness of its potential medicines. The company's journey reflects the long and often challenging path of bringing new drugs from the lab to patients.
What it actually does
Geron Corporation is a biopharmaceutical company, which means it researches, develops, and aims to commercialize medicines. Specifically, Geron is working on a type of drug that targets a process called telomerase. This enzyme is involved in cell aging and cancer cell growth. By developing inhibitors for telomerase, Geron hopes to create new treatments for certain blood cancers and related conditions, offering new options for patients who may have limited alternatives.
Oncology Therapeutics
Geron's primary business revolves around developing treatments for cancer, specifically focusing on a class of drugs known as telomerase inhibitors. Their lead product candidate, RYTELO, is designed to treat myelodysplastic syndromes (MDS), a group of blood disorders where the bone marrow doesn't produce enough healthy blood cells. The company is also advancing other drug candidates through various stages of clinical trials for related conditions like myelofibrosis and acute myeloid leukemia (AML), aiming to address unmet medical needs in these serious diseases.
What management is betting on now
Geron's current strategy is heavily focused on advancing its lead drug candidate, RYTELO, through the final stages of development and seeking regulatory approval for its use in treating myelodysplastic syndromes. Management is also investing in further clinical trials for other pipeline assets targeting myelofibrosis and acute myeloid leukemia. The success of these late-stage trials and subsequent approvals are critical for Geron to transition into a commercial-stage company and bring these potential new therapies to patients.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-58.94M
FY2024 Q4
$-44.09M
Revenue
$57.48M
Net income
$-16.68M
Diluted EPS
-0.02
Operating cash flow
$-15.83M
Free cash flow
—
Fetching…
Sources
Revenue
$51.84M
Net income
$-3.64M
Diluted EPS
-0.01
Operating cash flow
$-62.91M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-28.86M
Diluted EPS
-0.05
Operating cash flow
$-22.07M
Free cash flow
—
Fetching…
Sources
Revenue
$47.23M
Net income
$-18.43M
Diluted EPS
-0.03
Operating cash flow
$-13.58M
Free cash flow
—
Fetching…
Sources
Revenue
$49.04M
Net income
$-16.38M
Diluted EPS
-0.02
Operating cash flow
$-27.41M
Free cash flow
—
Fetching…
Sources
Revenue
$39.60M
Net income
$-19.84M
Diluted EPS
-0.03
Operating cash flow
$-47.98M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-25.35M
Diluted EPS
-0.04
Operating cash flow
$-43.95M
Free cash flow
$-44.09M
Fetching…
Sources
Revenue
$28.27M
Net income
$-26.45M
Diluted EPS
-0.04
Operating cash flow
$-58.94M
Free cash flow
$-58.94M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.97
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $178.7M - more cash than debt. Interest coverage -1.6x.
Net debt
$-178.70M
Interest coverage
-1.58x
Geron Corporation is healthier than 0 of 1 peers on balance-sheet leverage.
Healthy
Worse cushion
Baseline
Better cushion
GERN
BASELINE
Geron Corporation
Total debt $122.14M Interest coverage -1.58x This is the baseline the peer rows are being compared against.
What you should know
The case for and against GERN
1 Reward
1 Risk
Rewards
-
Revenue grew 86642.6% last year.
Risks
-
Return on equity was -28.3% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
24.21x
P/B
2.85x
P/S
3.04x
EV/EBITDA
-16.10x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
58.5%
Operating margin
-22.0%
Net margin
-33.1%
ROE
-28.3%
ROA
-4.1%
Health
Liquidity and balance-sheet strength
Debt / equity
0.56x
Current ratio
6.92x
Quick ratio
5.04x
Total debt
$122.14M
Total cash
$300.85M
Growth
How the business has been compounding
Revenue TTM
$205.58M
Revenue 5Y CAGR
-15.3%
EPS TTM
-0.11
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-114.38M
Free CF TTM
$-219.30M
FCF margin
-106.7%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—